Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$391M |
| 2 |
Pfizer
PFE
|
$268M |
| 3 |
Electronic Arts
EA
|
$247M |
| 4 |
Eli Lilly
LLY
|
$223M |
| 5 |
Colgate-Palmolive
CL
|
$215M |
Top Sells
| 1 |
Booking.com
BKNG
|
$358M |
| 2 |
AET
Aetna Inc
AET
|
$277M |
| 3 |
Xerox
XRX
|
$264M |
| 4 |
Meta Platforms (Facebook)
META
|
$262M |
| 5 |
Comcast
CMCSA
|
$260M |
Sector Composition
| 1 | Healthcare | 16.14% |
| 2 | Technology | 13.62% |
| 3 | Financials | 11.85% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
NetEase
NTES
$86.2B
| $820M | 1.05% | 2,726,000 +456,300 | +20% | +$137M |
|
2
Johnson & Johnson
JNJ
$427B
| $811M | 1.04% | 6,132,200 -970,500 | -14% | -$128M |
|
|
3
Bristol-Myers Squibb
BMY
$96B
| $752M | 0.96% | 13,488,200 +7,020,200 | +109% | +$391M |
|
4
Gilead Sciences
GILD
$140B
| $737M | 0.94% | 10,407,848 +2,700,600 | +35% | +$191M |
|
|
5
Colgate-Palmolive
CL
$67.9B
| $723M | 0.92% | 9,753,400 +2,903,800 | +42% | +$215M |
|
6
NVIDIA
NVDA
$4.24T
| $688M | 0.88% | 4,758,793 +768,200 | +19% | +$111M |
|
7
Humana
HUM
$36.5B
| $657M | 0.84% | 2,731,100 +39,400 | +1% | +$9.48M |
|
8
PepsiCo
PEP
$204B
| $652M | 0.83% | 5,642,700 +1,298,900 | +30% | +$150M |
|
9
Domino's
DPZ
$15.6B
| $647M | 0.83% | 3,060,900 +930,200 | +44% | +$197M |
|
10
Amgen
AMGN
$155B
| $586M | 0.75% | 3,400,145 +986,700 | +41% | +$170M |
|
11
Novo Nordisk
NVO
$251B
| $580M | 0.74% | 13,534,300 -2,874,900 | -18% | -$123M |
|
12
Mastercard
MA
$538B
| $535M | 0.68% | 4,403,900 -848,800 | -16% | -$103M |
|
13
Crown Castle
CCI
$43.2B
| $488M | 0.62% | 4,875,503 +876,900 | +22% | +$87.8M |
|
14
VeriSign
VRSN
$25.5B
| $469M | 0.6% | 5,045,476 +941,100 | +23% | +$87.5M |
|
|
15
Eli Lilly
LLY
$657B
| $469M | 0.6% | 5,694,905 +2,714,505 | +91% | +$223M |
|
16
IBM
IBM
$227B
| $418M | 0.53% | 2,720,300 +696,600 | +34% | +$107M |
|
|
BCR
17
DELISTED
CR Bard Inc.
BCR
| $410M | 0.52% | 1,295,600 +338,900 | +35% | +$107M |
|
18
GSK
GSK
$79.9B
| $403M | 0.51% | 9,338,000 +4,935,900 | +112% | +$213M |
|
19
Cboe Global Markets
CBOE
$24.7B
| $399M | 0.51% | 4,369,996 -97,304 | -2% | -$8.89M |
|
20
Walmart
WMT
$774B
| $383M | 0.49% | 5,063,100 +19,700 | +0.4% | +$1.49M |
|
21
Philip Morris
PM
$260B
| $360M | 0.46% | 3,066,800 +1,139,900 | +59% | +$134M |
|
22
Chubb
CB
$110B
| $350M | 0.45% | 2,404,461 +449,500 | +23% | +$65.3M |
|
23
American Electric Power
AEP
$59.4B
| $332M | 0.42% | 4,778,600 +394,800 | +9% | +$27.4M |
|
24
Northrop Grumman
NOC
$84.5B
| $320M | 0.41% | 1,245,400 +256,200 | +26% | +$65.8M |
|
|
TWX
25
DELISTED
Time Warner Inc
TWX
| $313M | 0.4% | 3,117,334 +439,000 | +16% | +$44.1M |
|